`
`
`Paper No. _____
`Filed: January 30, 2019
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_____________________________
`
`MODERNA THERAPEUTICS, INC.,
`Petitioner,
`
`v.
`
`ARBUTUS BIOPHARMA CORPORATION,
`Patent Owner.
`_____________________________
`
`Case IPR2019-00554
`Patent No. 8,058,069
`_____________________________
`
`
`PATENT OWNER ARBUTUS BIOPHARMA CORPORATION’S
`MANDATORY NOTICES UNDER 37 C.F.R. § 42.8
`
`
`
`
`
`
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.8, the undersigned on behalf of and acting in a
`
`representative capacity for Patent Owner Arbutus Biopharma Corporation
`
`(“Arbutus”), hereby submits the following mandatory notices in connection with
`
`the petition for inter partes review of U.S. Patent No. 8,058,069, Case IPR2019-
`
`00554.
`
`A. Real Party-In-Interest
`
`
`
`In accordance with 37 C.F.R. § 42.8(b)(1), Patent Owner identifies Arbutus
`
`Biopharma Corporation (fka “Tekmira”). Protiva Biotherapeutics, Inc. existed as a
`
`wholly-owned subsidiary of Arbutus Biopharma Corporation. Protiva
`
`Biotherapeutics, Inc. was amalgamated into Arbutus Biopharma Corporation in
`
`January 2018. Patent Owner further identifies Genevant Sciences Ltd. and its fully
`
`owned subsidiaries: Genevant Sciences Holding, Ltd., Genevant Sciences
`
`Corporation, Genevant Sciences, Inc., and Genevant Sciences, GmbH.
`
`B. Related Matters
`
`
`
`In accordance with 37 C.F.R. § 42.8(b)(2), Patent Owner identifies the
`
`following related matters:
`
`
`
`Moderna Therapeautics, Inc. v. Protiva Biotherapeutics, Inc.,
`
`IPR2018-00680 regarding U.S. Patent No. 9,404,127; Moderna Therapeautics, Inc.
`
`v. Protiva Biotherapeutics, Inc., IPR2018-00739 regarding U.S. Patent No.
`
`-2-
`
`
`
`9,364,435; and European Patent Office Opposition proceedings regarding EP 2 279
`
`254.
`
`C. Lead and Back-up Counsel
`
`
`
`In accordance with 37 C.F.R. § 42.8(b)(3), Patent Owner provides the
`
`following designation of counsel:
`
`Lead Counsel
`Michael T. Rosato
`USPTO Reg. No. 52,182
`WILSON SONSINI GOODRICH &
`ROSATI
`701 Fifth Avenue, Suite 5100
`Seattle, WA 98104-7036
`Tel.: 206-883-2529
`Fax: 206-883-2699
`Email: mrosato@wsgr.com
`
`
`Back-Up Counsel
`Steven W. Parmelee
`USPTO Reg. No. 31,990
`WILSON SONSINI GOODRICH &
`ROSATI
`701 Fifth Avenue, Suite 5100
`Seattle, WA 98104-7036
`Tel.: 206-883-2542
`Fax: 206-883-2699
`Email: sparmelee@wsgr.com
`Sonja R. Gerrard
`USPTO Reg. No. 72,802
`WILSON SONSINI GOODRICH &
`ROSATI
`701 Fifth Avenue, Suite 5100
`Seattle, WA 98104-7036
`Tel.: 206-883-2649
`Fax: 206-883-2699
`Email: sgerrard@wsgr.com
`
`D. Electronic Service
`
`Patent Owner consents to electronic service by email at the email addresses
`
`provided above.
`
`-3-
`
`
`
`
`
`Date: January 30, 2019
`
`
`
`Respectfully submitted,
`
`
`/ Michael T. Rosato /
`Michael T. Rosato, Lead Counsel
`Reg. No. 52,182
`
`
`
`
`
`
`
`-4-
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned certifies that the foregoing Patent Owner Arbutus
`
`Biopharma Corporation’s Mandatory Notices Under 37 C.F.R. § 42.8 and
`
`accompanying Powers of Attorney were served on January 30, 2019, at the
`
`following electronic service addresses:
`
`Michael Fleming
`C. Maclain Wells
`IRELL & MANELLA LLP
`mfleming@irell.com
`mwells@irell.com
`ModernaIPR@irell.com
`
`
`Date: January 30, 2019
`
`
`
`
`
`
`/ Michael T. Rosato /
`Michael T. Rosato, Lead Counsel
`Reg. No. 52,182
`
`
`
`
`
`-5-
`
`